Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: N Engl J Med. 2018 Apr 16;378(22):2093–2104. doi: 10.1056/NEJMoa1801946

Figure 2. Efficacy of Nivolumab plus Ipilimumab versus Chemotherapy in Patients with a High Tumor Mutational Burden.

Figure 2.

A high tumor mutational burden was defined as at least 10 mutations per megabase. In Panel A, the 95% confidence interval for the hazard ratio for disease progression or death was 0.43 to 0.77. In both panels, the circles (for nivolumab plus ipilimumab) and triangles (for chemotherapy) indicate censored data. NR denotes not reached.